Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension
Authors:
- Hossein A. GhofraniHossein A. Ghofrani
- Robert VoswinckelRVRobert Voswinckel
- Frank ReichenbergerFRFrank Reichenberger
- Horst OlschewskiHOHorst Olschewski
- Peter HaredzaPHPeter Haredza
- Burcu KaradaşBKBurcu Karadaş
- Ralph T. SchermulyRalph T. Schermuly
- Norbert WeissmannNorbert Weissmann
- Werner SeegerWerner Seeger
- Friedrich GrimmingerFriedrich Grimminger
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Beraprost therapy for pulmonary arterial hypertensionJACC, 2003
- Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated AnalysesJournal of Urology, 2002
- VardenafilExpert Opinion on Investigational Drugs, 2002
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial HypertensionCirculation, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- IC351 (tadalafil, Cialis): update on clinical experienceInternational Journal Of Impotence Research, 2002
- Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertensionJACC, 2001
- GENERAL CARDIOLOGY: Pulmonary arterial hypertension: new ideas and perspectivesHeart, 2001
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996